64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

This trial tests a new radioactive treatment for advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses a radioactive copper compound that finds and attaches to a protein called PSMA, which is found on prostate cancer cells, then delivers radiation directly to tumors throughout the body. **You may be eligible if...** - You are 18 or older with confirmed, spread prostate cancer that no longer responds to hormone-lowering therapy - Your cancer showed PSMA activity on a special PET scan - Your testosterone levels are at castrate levels (very low) - You have previously tried at least one advanced hormone therapy drug (such as enzalutamide or abiraterone) - Your cancer is still progressing despite treatment (rising PSA, new lesions, or new bone involvement) - Your overall health status is acceptable (ECOG 0–2) with life expectancy over 6 months **You may NOT be eligible if...** - You have not tried any advanced hormone therapy - Your cancer has not shown clear signs of progression - You have serious kidney, liver, or bone marrow problems - You are unwilling to follow contraception requirements during the study Talk to your doctor to see if this trial is right for you.